MeSH tree: C04.588.894.797.520
A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment.
Jan 21, 2026
0
29
A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC complex, a critical cellular ...
Jan 19, 2026
0
45
After increasing for more than 25 years, lung cancer death rates are finally leveling off among women in European Union (EU) countries apart from Spain, according to predictions of mortality rates from the disease for 2026.
Jan 18, 2026
0
20
UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing ...
Jan 14, 2026
0
50
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting ...
Jan 14, 2026
0
11
Just outside Salt Lake City sits an old, two-story, brick hotel. It's been given new life as a homeless shelter for seniors. The Medically Vulnerable People shelter—or MVP shelter, as it's known—is for people 62 and older ...
Jan 12, 2026
0
8
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises questions about sustainability, prevention ...
Jan 12, 2026
0
16
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment.
Jan 7, 2026
0
21
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to chemotherapy. However, patients ...
Dec 23, 2025
0
44
Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided mixed benefits for patients while costing Medicare billions of dollars, reveals research published ...
Dec 21, 2025
0
33
